A

AC Immune SA

D
ACIU
USD
0.08
(2.2039%)
Market Closed
3,636.00
Volume
-0.91
EPS
-
Div Yield
-4.908446
P/E
367,068,468.48
Market Cap
Today
2.2039%
1 Week
21.959%
1 Month
9.118%
6 Months
10.417%
12 Months
22.039%
Year To Date
-25.800%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ADCT
0.13
(4.2071%)
USD
T
TTOO
0.05
(2.3256%)
USD
A
ABEO
0.36
(6.6055%)
USD
A
ARCT
0.49
(2.3833%)
USD
V
VTVT
0.85
(6.0369%)
USD
K
KPTI
-0.0002
(-0.027%)
USD
O
ONCT
0.04
(2.3952%)
USD
C
CDTX
0.16
(1.3617%)
USD
S
SELB
-0.0702
(-7.3871%)
USD
G
GH
0.3
(1.1952%)
USD

Title:
AC Immune SA

Sector:
Healthcare
Industry:
Biotechnology
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Do you need help or have a question?
Contact Us